Seres Therapeutics
Cambridge
About Seres Therapeutics
Seres Therapeutics develops and delivers therapies composed of live bacterial consortia that aim to modulate the human gut microbiome for therapeutic benefit. The company’s platform draws on insights into microbial ecology, host immune function, and gut barrier integrity to create oral treatments that act via multiple biological pathways. Its pipeline includes products designed to prevent infectious complications and antimicrobial-resistant bloodstream infections in vulnerable patient populations, as well as treatments for inflammatory and immune-related gastrointestinal disorders. Seres translates microbiome research into clinical development, manufacture, and commercialization of these novel live biotherapeutic medicines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $541.4M
- Funding stage: IPO
- Last round: Grant (Oct 2025)
- Ticker: nasdaq:MCRB
- Website: serestherapeutics.com
- Phone: +1 617 945 9626
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/seres-therapeutics-130846 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.